Search

Displaying results 4331 - 4340 of 10000 in total
  1. Drug

    L523S

    go.drugbank.com/drugs/DB06498
    Investigational

    According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) … and when delivered following incorporation into an E1B-deleted adenovirus (Ad/L523S)."

  2. Drug

    TAS-108

    go.drugbank.com/drugs/DB05966
    Investigational

  3. Drug

    Rupintrivir

    go.drugbank.com/drugs/DB05102
    Experimental

    Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus. … Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections.

  4. Drug

    AZD-8330

    go.drugbank.com/drugs/DB06061
    Investigational

    AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. … AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.

  5. Drug

    Zenarestat

    go.drugbank.com/drugs/DB02132
    Experimental

  6. Drug

    Veligrotug

    go.drugbank.com/drugs/DB18976
    Approved

    [L63798] Thyroid eye disease has historically been managed differently depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the … [L63929] The FDA approved veligrotug-vvze on June 26, 2026, for the treatment of thyroid eye disease regardless of disease activity or duration.[L63798,L63929]

  7. Drug

    Tinidazole

    go.drugbank.com/drugs/DB00911
    ApprovedInvestigational

    A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections.

  8. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models

  9. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  10. Drug

    ATL1102

    go.drugbank.com/drugs/DB04997
    Investigational

    ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.